Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announces the launch of its Quantum Flex Cell Expansion System, a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo BCT identified the industry’s need for earlier automation to potentially limit additional and time-consuming steps such as bridging studies and technology transfers. Quantum Flex allows developers to complete their early process development on the same platform they will use for manufacturing, creating a cell culture environment where cells thrive. Early process development may lead to reduced cost and risk of unanticipated process deviations in later phases of clinical trials.
LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, and Immunicom, Inc., a clinical-stage biotech pioneering subtractive immunotherapies, today announce the signing of a co-commercialization agreement.
Terumo Blood and Cell Technologies today launches the Advanced Therapy Manufacturing and Innovation (ATMI) Grant 2020 for the Asia Pacific region.
Mallinckrodt plc, a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies have announced that UVADEX® (methoxsalen) has received regulatory approval in Australia by the Australian Therapeutic Goods Administration (TGA) for extracorporeal administration with the THERAKOS® CELLEX® Photopheresis System.
Terumo Corporation (TSE: 4543) announced today that it acquired CE marking for the Ultimaster™ Tansei™ drug eluting stent (DES). Looking ahead, Terumo will begin sales of the product in Europe in May 2018. On January 24, 2018, Terumo received approval to manufacture and sell Ultimaster Tansei in Japan, and it plans to release the product in the second half of fiscal 2018.
The National Institute for Health and Care Excellence has changed its position on the use of MSD’s Ezetrol on the National Health Service, reverting back to original guidelines published in 2007.
Japan Vaccine seeks approval to sell intradermal seasonal influenza vaccine in Japan